Polypharmacy and relapse of schizophrenia: are they related?
Introduction Polypharmacy can be the cause of deliberate discontinuation of medication and consequent relapse of schizophrenia. Objectives To establish the one-year rate of relapse in the patients with schizophrenia with regard to monotherapy or polypharmacy. Methods The sample of all hospitalize...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2022-06-01
|
| Series: | European Psychiatry |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822019757/type/journal_article |
| Summary: | Introduction
Polypharmacy can be the cause of deliberate discontinuation of medication and consequent relapse of schizophrenia.
Objectives
To establish the one-year rate of relapse in the patients with schizophrenia with regard to monotherapy or polypharmacy.
Methods
The sample of all hospitalized patients with schizophrenia in a five-year period was analyzed. Descriptive statistics were used.
Results
Total of 87 participants (57 women), the median age was 43 years. Antipsychotic monotherapy was used in 31 (35.6%) of the participants. In one year period, 32 (36.8%) of all participants had a relapse. Prior to relapse, significantly more participants were treated with polypharmacy (p<0,05).
Conclusions
Antipsychotic polypharmacy is related to a higher rate of relapse in patients with schizophrenia.
Disclosure
No significant relationships.
|
|---|---|
| ISSN: | 0924-9338 1778-3585 |